TY - JOUR
T1 - Liquid biopsies in patients with diffuse glioma
AU - Best, Myron G.
AU - Sol, Nik
AU - Zijl, Sebastiaan
AU - Reijneveld, Jaap C.
AU - Wesseling, Pieter
AU - Wurdinger, Thomas
N1 - Publisher Copyright:
© 2015, The Author(s).
PY - 2015/6/26
Y1 - 2015/6/26
N2 - Diffuse gliomas are the most common malignant primary tumors of the central nervous system. Like other neoplasms, these gliomas release molecular information into the circulation. Tumor-derived biomarkers include proteins, nucleic acids, and tumor-derived extracellular vesicles that accumulate in plasma, serum, blood platelets, urine and/or cerebrospinal fluid. Recently, also circulating tumor cells have been identified in the blood of glioma patients. Circulating molecules, vesicles, platelets, and cells may be useful as easily accessible diagnostic, prognostic and/or predictive biomarkers to guide patient management. Thereby, this approach may help to circumvent problems related to tumor heterogeneity and sampling error at the time of diagnosis. Also, liquid biopsies may allow for serial monitoring of treatment responses and of changes in the molecular characteristics of gliomas over time. In this review, we summarize the literature on blood-based biomarkers and their potential value for improving the management of patients with a diffuse glioma. Incorporation of the study of circulating molecular biomarkers in clinical trials is essential for further assessment of the potential of liquid biopsies in this context.
AB - Diffuse gliomas are the most common malignant primary tumors of the central nervous system. Like other neoplasms, these gliomas release molecular information into the circulation. Tumor-derived biomarkers include proteins, nucleic acids, and tumor-derived extracellular vesicles that accumulate in plasma, serum, blood platelets, urine and/or cerebrospinal fluid. Recently, also circulating tumor cells have been identified in the blood of glioma patients. Circulating molecules, vesicles, platelets, and cells may be useful as easily accessible diagnostic, prognostic and/or predictive biomarkers to guide patient management. Thereby, this approach may help to circumvent problems related to tumor heterogeneity and sampling error at the time of diagnosis. Also, liquid biopsies may allow for serial monitoring of treatment responses and of changes in the molecular characteristics of gliomas over time. In this review, we summarize the literature on blood-based biomarkers and their potential value for improving the management of patients with a diffuse glioma. Incorporation of the study of circulating molecular biomarkers in clinical trials is essential for further assessment of the potential of liquid biopsies in this context.
KW - Liquid biopsies
KW - Malignant glioma
KW - Minimally invasive biomarkers
KW - Molecular diagnostics
UR - http://www.scopus.com/inward/record.url?scp=84929706385&partnerID=8YFLogxK
U2 - 10.1007/s00401-015-1399-y
DO - 10.1007/s00401-015-1399-y
M3 - Review article
C2 - 25720744
AN - SCOPUS:84929706385
SN - 0001-6322
VL - 129
SP - 849
EP - 865
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 6
M1 - 1399
ER -